© Reuters. File photo: On December 16, 2021, the logo of Valneva, a biotech company, can be seen outside the headquarters in Vienna, Austria. REUTERS/Lisi Niesner
PARIS (Reuters)-The share price of biotech company Valneva fell again on Wednesday, falling for the seventh consecutive day as investors increasingly believe that COVID-19 Omicron variants may reduce the need for mass vaccination.
At 0945 GMT, Valneva’s share price fell 3% to 17.10 euros, which means that the stock has fallen nearly 40% since its closing price of 26.38 euros on December 27.
As Valneva’s COVID-19 vaccine candidate gets closer and closer to approval, its annual growth rate in 2021 and 2020 has indeed exceeded 200%. It is still waiting for its green light in the European Union and the United Kingdom.
A Paris analyst said: “The decline in stock prices seems to be mainly driven by retail investors, who believe that no new vaccination activities are needed after the Omicron wave.”
Since the beginning of this year, the stock prices of companies that have approved COVID-19 vaccines have also fallen, among which Pfizer (New York Stock Exchange:) fell 7.65% in the past two days and Modern (NASDAQ:) fell 8.2%.
Preliminary data from various countries/regions seem to indicate that Omicron is by far the most contagious of all COVID variants, and new cases in many countries/regions have reached record levels—it is more likely to send an infected person to the hospital. small.
Converged Media Fusion Media or anyone associated with Fusion Media shall not be liable for any loss or damage caused by reliance on the data, quotations, charts, and buy/sell signals contained in this website. Please fully understand the risks and costs associated with financial market transactions. This is one of the most risky forms of investment.